Merck Healthcare Kgaa, Darmstadt, Germany, An Affiliate Of Merck Kgaa, Darmstadt, Germany
Clinical trials sponsored by Merck Healthcare Kgaa, Darmstadt, Germany, An Affiliate Of Merck Kgaa, Darmstadt, Germany, explained in plain language.
-
New IVF drug trial offers hope for women with rare hormone deficiency
Disease control Recruiting nowThis study is testing whether a new combination of two fertility hormones works better and is as safe as the standard treatment for Japanese women who lack specific hormones needed for egg development. About 333 women who need help getting pregnant through IVF will receive either…
Phase: PHASE3 • Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC
-
New oral pill could help control debilitating Muscle-Weakening disease
Disease control Recruiting nowThis study is testing whether a new oral formulation of a drug called cladribine can help control symptoms and improve daily life for adults with generalized myasthenia gravis (gMG), a chronic autoimmune disease that causes muscle weakness. It will compare the pill against a plac…
Phase: PHASE3 • Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Mar 24, 2026 12:03 UTC
-
First test of new drug in healthy volunteers
Knowledge-focused Recruiting nowThis is an early-stage study to check the safety of a new drug called M5542 when given as an injection to healthy people. Researchers will give different doses to small groups of participants and closely monitor for any side effects. The main goal is to see how the body handles t…
Phase: PHASE1 • Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Knowledge-focused
Last updated Apr 01, 2026 21:56 UTC
-
Scientists test drug safety in people with kidney problems
Knowledge-focused Recruiting nowThis early-stage study aims to understand how kidney function affects the way a new drug called enpatoran moves through the body. Researchers will compare a single dose in 40 people with normal kidney function to those with impaired kidney function. The main goal is to measure dr…
Phase: PHASE1 • Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:34 UTC